Key result
Heparin improves arterial patency to ~73% while aspirin and dipyridamole selectively boost venous patency.
Why the study?
Do systemic antithrombotic agents (heparin, aspirin/dipyridamole) improve arterial and venous patency in rat models of microvascular thrombosis?
Population
Rat models of microvascular thrombosis, n=60
Comparison
Systemic heparin, aspirin and dipyridamole, or a… vs Dual controls (vehicle treated)
Design
Preclinical
Follow-up
7 days
Authors
Loading...
Suggests vessel-specific antithrombotic tailoring in microsurgery models; leaves open human translation pending clinical studies.
Do systemic antithrombotic agents (heparin, aspirin/dipyridamole) improve arterial and venous patency in rat models of microvascular thrombosis?
In a rat model of microvascular thrombosis, heparin improved arterial but not venous patency, while aspirin and dipyridamole improved venous but not arterial patency, contrasting with classic theories of thrombosis.
Li et al. (1995) studied Arterial and venous microvascular thrombosis (n=60). Systemic heparin, aspirin and dipyridamole, or both vs. Vehicle treated (dual controls) was evaluated on 1-day patency rates in arterial and venous models. Heparin improved 1-day arterial patency to 73.3% (vs 13.4% control) but not venous, whereas aspirin and dipyridamole improved venous patency to 40% (vs 0% control) but not arterial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: